Dopamine D1 receptor antagonist reduces stimulant-induced conditioned place preferences and dopamine receptor supersensitivity.
Animals
Benzazepines
/ pharmacology
Central Nervous System Stimulants
Cocaine
Conditioning, Psychological
/ drug effects
Dopamine Antagonists
/ pharmacology
Locomotion
Male
Methamphetamine
Rats
Rats, Sprague-Dawley
Receptors, Dopamine D1
/ antagonists & inhibitors
Receptors, Dopamine D2
Sulpiride
/ pharmacology
Addiction
Cocaine
Dopamine receptor subtype
Dopamine receptor supersensitivity
Methamphetamine
Journal
Naunyn-Schmiedeberg's archives of pharmacology
ISSN: 1432-1912
Titre abrégé: Naunyn Schmiedebergs Arch Pharmacol
Pays: Germany
ID NLM: 0326264
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
23
01
2019
accepted:
12
07
2019
pubmed:
3
8
2019
medline:
1
1
2021
entrez:
3
8
2019
Statut:
ppublish
Résumé
Repeated administration of stimulants induces conditioned place preference (CPP). Dopamine receptor supersensitivity is developed in stimulant-induced CPP animals; however, dopamine receptor subtypes associated with the development of supersensitivity in CPP animals are largely unknown. The present preclinical study aimed to examine whether dopamine D1 or D2 receptor antagonists exert inhibitory effects on stimulant-induced psychological behaviors. Additionally, the authors aimed to elucidate the role of dopamine receptor supersensitivity on the development of reward-related behavior. Sprague Dawley rats subjected to methamphetamine- and cocaine-induced CPP tests were treated with dopamine D1 (SCH23390) or D2 (sulpiride) receptor antagonists. Following the CPP experiment, rats were challenged with apomorphine (dopamine receptor agonist), and locomotor activity was measured. Methamphetamine- and cocaine-induced CPP was reduced with the administration of SCH23390, but not sulpiride. In addition, the apomorphine challenge evoked an increase in locomotor activity in stimulant-pre-treated rats, reflecting dopamine receptor supersensitivity. SCH23390 pre-treatment inhibited the development of dopamine receptor supersensitivity, while sulpiride demonstrated no inhibitory effects. These results suggest that the dopamine D1 receptor antagonist SCH23390 inhibits the development of dopamine receptor supersensitivity which is associated with the development of CPP.
Identifiants
pubmed: 31372696
doi: 10.1007/s00210-019-01694-3
pii: 10.1007/s00210-019-01694-3
doi:
Substances chimiques
Benzazepines
0
Central Nervous System Stimulants
0
DRD2 protein, rat
0
Dopamine Antagonists
0
Drd1 protein, rat
0
Receptors, Dopamine D1
0
Receptors, Dopamine D2
0
SCH 23390
0
Methamphetamine
44RAL3456C
Sulpiride
7MNE9M8287
Cocaine
I5Y540LHVR
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
131-138Commentaires et corrections
Type : ErratumIn
Références
Eur Neuropsychopharmacol. 2008 Aug;18(8):551-6
pubmed: 18284941
Pharmacol Biochem Behav. 2011 May;98(3):449-54
pubmed: 21334368
Behav Brain Res. 1999 Aug;103(1):55-61
pubmed: 10475164
PLoS One. 2013 Nov 04;8(11):e78258
pubmed: 24223783
Pharmacol Biochem Behav. 1995 Jan;50(1):23-7
pubmed: 7700950
Brain Res Bull. 1996;40(3):201-7
pubmed: 8736582
J Ethnopharmacol. 1998 Feb;60(1):33-42
pubmed: 9533430
Brain Res Brain Res Rev. 1993 Sep-Dec;18(3):247-91
pubmed: 8401595
J Pharmacol Exp Ther. 1994 Jul;270(1):209-18
pubmed: 8035317
Pharmacol Biochem Behav. 1996 Sep;55(1):11-7
pubmed: 8870032
Int J Neurosci. 2010 Nov;120(11):691-7
pubmed: 20942582
Pharmacol Biochem Behav. 1991 Jun;39(2):465-8
pubmed: 1682950
J Ethnopharmacol. 1999 Jul;66(1):25-31
pubmed: 10432204
Biol Psychiatry. 2014 Jul 1;76(1):2-3
pubmed: 24925888
Nat Neurosci. 2013 May;16(5):632-8
pubmed: 23542690
Eur J Neurosci. 2009 Apr;29(8):1641-53
pubmed: 19419427
Acta Pharmacol Sin. 2016 Feb;37(2):157-65
pubmed: 26687935
Neurosci Biobehav Rev. 2018 Jun;89:13-28
pubmed: 29577963
Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3513-8
pubmed: 15716360
J Pharmacol Exp Ther. 2007 Nov;323(2):599-605
pubmed: 17675585
Eur J Pharmacol. 2014 Nov 15;743:126-32
pubmed: 25261038
Synapse. 1998 Oct;30(2):181-93
pubmed: 9723788
Pharmacol Res. 2001 Dec;44(6):473-9
pubmed: 11735353
Chin J Physiol. 1998 Jun 30;41(2):85-92
pubmed: 9801838
Pharmacol Biochem Behav. 1999 Jul;63(3):407-12
pubmed: 10418781
Pharmacol Biochem Behav. 1995 Dec;52(4):759-63
pubmed: 8587917
J Pharmacol Exp Ther. 2009 Aug;330(2):633-40
pubmed: 19448141
Am Psychol. 2016 Nov;71(8):670-679
pubmed: 27977239
Psychopharmacology (Berl). 2007 Apr;191(3):719-30
pubmed: 16835769
Psychopharmacology (Berl). 2005 Jun;180(1):21-32
pubmed: 15682301
Psychopharmacology (Berl). 2016 Mar;233(5):893-903
pubmed: 26650612
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jul 3;52:9-16
pubmed: 23793001
Neuropsychopharmacology. 2001 Feb;24(2):97-129
pubmed: 11120394
Mol Neurobiol. 2015 Dec;52(3):1152-1164
pubmed: 25307288
Behav Pharmacol. 2001 Dec;12(8):603-11
pubmed: 11856897
Postgrad Med. 2009 Nov;121(6):176-96
pubmed: 19940429